TrianglePacritinib (NCT07033598)
Pacritinib trial for Leukemia, Myelomonocytic, Chronic (NCT07033598). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with proliferative CMML-1, a high white-cell count, and qualifying spleen enlargement, symptoms, or low platelets. Prior JAK-inhibitor treatment is excluded.
The idea: pacritinib blocks JAK2 and FLT3 signaling; hydroxyurea interferes with DNA production. Patients are randomized to pacritinib 200 milligrams twice daily or hydroxyurea, for up to 48 weeks. Researchers assess blood counts, spleen size, and symptoms without leukemic transformation. Eligible patients lacking benefit on hydroxyurea may switch to pacritinib under safety criteria.
This phase 2 study plans 66 patients. Theradex sponsors it; four US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.